Correction to: Scientific Reports https://doi.org/10.1038/s41598-017-18892-9, published online 15 January 2018
This Article contains errors in the Methods section, under subsection ‘Cloning of antibodies’.
“VL and VH genes of Trastuzumab (PDB: 1N8Z) and Pertuzumab (PDB: 1S78) were synthesized (Blue Heron Biotech LLC). The VL were joined to Cκ (Accession no: AKL91149.1) and Cλ (Cλ1: Accession X51755; Cλ2: Accession J00253; Cλ3: Accession X06876; Cλ6: Accession J03011; Cλ7: Accession X51755) forming the light chain, while the VH were joined to CH isotype/subtypes (CHμ: Accession AAS01769.1; CHα1: Accession P01876.2; CHα2: Accession AAT74071.1; CHγ1: Accession AAA02914.1; CHγ2: Accession AAG00910.2; CHγ3: Accession P01860.2; CHγ4: Accession P01861.1; CHδ: Accession AAA52770.1; and CHε: Accession P01854.1) to form the heavy chain construct in cloning cassettes previously described36. The cassettes were cloned into pTT5 plasmid (YouBio) and transformed into competent DH5α bacteria37 as previously described.”
should read:
“VL and VH genes of Trastuzumab (PDB: 1N8Z) and Pertuzumab (PDB: 1S78) were synthesized (Blue Heron Biotech LLC). The VL were joined to Cκ (Accession no: AKL91149.1) and Cλ (Cλ1: Accession P0CG04.1; Cλ2: Accession P0DOY2.1; Cλ3: Accession P0DOY3.1; Cλ6: Accession P0CF74.1; Cλ7: Accession AAB59435.1) forming the light chain, while the VH were joined to CH isotype/subtypes (CHμ: Accession AAS01769.1; CHα1: Accession P01876.2; CHα2: Accession AAT74071.1; CHγ1: Accession AAA02914.1; CHγ2: Accession AAG00910.2; CHγ3: Accession P01860.2; CHγ4: Accession P01861.1; CHδ: Accession AAA52770.1; and CHε: Accession P01854.1) to form the heavy chain construct in cloning cassettes previously described 36. The cassettes were cloned into pTT5 plasmid (YouBio) and transformed into competent DH5α bacteria37 as previously described.”
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lua, WH., Ling, WL., Yeo, J.Y. et al. Author Correction: The effects of Antibody Engineering CH and CL in Trastuzumab and Pertuzumab recombinant models: Impact on antibody production and antigen-binding. Sci Rep 8, 11110 (2018). https://doi.org/10.1038/s41598-018-29097-z
Published:
DOI: https://doi.org/10.1038/s41598-018-29097-z
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
